Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serenixol
- Development stage
- Preclinical
01
Overview
Serenixol is referenced as a drug used in maintenance treatment regimens, specifically mentioned in the context of combination therapy for certain cancers. In at least one clinical trial, serenixol is administered as a maintenance therapy at a dose of 60 mg weekly until disease progression or intolerable toxicity. However, there is no detailed publicly available information on its chemical structure, mechanism of action, modality, or specific developer. It appears to be an investigational agent and not an established pharmaceutical with broad regulatory approval or well-documented pharmacology[4].
- Brand names
- serenixol
- Other names
- serenixol
Beyond the preview
Go deeper on serenixol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serenixol.